Cargando…
High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study
A prospective randomized phase III study was performed to evaluate whether intensified cytarabine would induce a higher response rate and longer event-free interval as compared to low-dose cytarabine in chronic myeloid leukemia (CML). One hundred and eighteen patients with CML in early chronic phase...
Autores principales: | Deenik, W., van der Holt, B., Verhoef, G. E. G., Schattenberg, A. V. M. B., Verdonck, L. F., Daenen, S. M. G. J., Zachée, P., Westveer, P. H. M., Smit, W. M., Wittebol, S., Schouten, H. C., Löwenberg, B., Ossenkoppele, G. J., Cornelissen, J. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101742/ https://www.ncbi.nlm.nih.gov/pubmed/17031690 http://dx.doi.org/10.1007/s00277-006-0186-1 |
Ejemplares similares
-
High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population
por: Kockerols, Camille C.B., et al.
Publicado: (2023) -
Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022) -
Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022) -
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
por: Halpern, Anna B., et al.
Publicado: (2023) -
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results
por: Cortes, Jorge E., et al.
Publicado: (2018)